Aktis Oncology (NASDAQ:AKTS) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a report released on Monday morning, MarketBeat reports. The firm issued a buy rating and a $30.00 price objective on the technology company’s stock.

A number of other brokerages have also weighed in on AKTS. JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price target for the company. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Bank of America assumed coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 target price on the stock. TD Cowen assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating for the company. Finally, Leerink Partners initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $31.25.

Aktis Oncology Stock Performance

Shares of Aktis Oncology stock opened at $19.06 on Monday. Aktis Oncology has a 1-year low of $16.80 and a 1-year high of $29.16. The firm’s fifty day simple moving average is $19.78.

Insider Transactions at Aktis Oncology

In other Aktis Oncology news, major shareholder Vida Ventures Ii, Llc purchased 835,000 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the transaction, the insider owned 5,671,825 shares in the company, valued at $102,092,850. This represents a 17.26% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ansbert Gadicke purchased 1,112,777 shares of the company’s stock in a transaction on Monday, January 12th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the acquisition, the insider directly owned 10,260,064 shares of the company’s stock, valued at $184,681,152. This represents a 12.17% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 6,117,776 shares of company stock valued at $110,119,968 in the last 90 days.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.